Emergent BioSolutions Inc. (NYSE: EBS) has announced the receipt of a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply Cyfendus® (anthrax vaccine adsorbed, adjuvanted). This follows a previous contract modification of $50 million in December 2024. Deliveries are expected to commence this calendar year and be completed by March 2026.
Cyfendus® was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals aged 18 through 65 years when administered with recommended antibacterial drugs.
The company's Senior Vice President, Paul Williams, stated that the new contract modification represents the next step in their ongoing engagement with the U.S. government, aiming to ensure the availability of medical countermeasures such as the Cyfendus® vaccine to protect civilian populations against the potential threat of anthrax.
Anthrax is classified as a tier 1 biological threat due to its potential for use in a bioterrorist incident, posing a threat to public health and national security. The Cyfendus® vaccine is intended for the post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis.
The contract modification signifies Emergent Biosolutions' continued support of the U.S. government's national security priorities through leveraging a U.S.-based supply chain for their anthrax vaccines. It is noted that the project has been supported in part with federal funds from the U.S. Department of Health and Human Services.
The press release did not provide specific financial metrics or comparisons with the previous period. Following these announcements, the company's shares moved -0.66%, and are now trading at a price of $7.58. For more information, read the company's full 8-K submission here.
